Bleakley Financial Group LLC Takes $2.91 Million Position in VanEck Biotech ETF $BBH

Bleakley Financial Group LLC purchased a new stake in VanEck Biotech ETF (NASDAQ:BBH) in the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 18,980 shares of the company’s stock, valued at approximately $2,909,000.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Ameritas Advisory Services LLC acquired a new position in VanEck Biotech ETF during the 2nd quarter worth approximately $57,000. Simplex Trading LLC grew its holdings in VanEck Biotech ETF by 100.8% during the first quarter. Simplex Trading LLC now owns 474 shares of the company’s stock worth $74,000 after purchasing an additional 238 shares during the period. SVB Wealth LLC acquired a new position in shares of VanEck Biotech ETF during the 1st quarter worth approximately $90,000. Strategic Financial Services Inc. acquired a new position in shares of VanEck Biotech ETF in the first quarter valued at $203,000. Finally, Flagship Harbor Advisors LLC grew its stake in VanEck Biotech ETF by 9.8% in the 1st quarter. Flagship Harbor Advisors LLC now owns 2,179 shares of the company’s stock valued at $343,000 after buying an additional 195 shares during the last quarter. 32.05% of the stock is owned by institutional investors and hedge funds.

VanEck Biotech ETF Trading Down 0.0%

Shares of NASDAQ BBH opened at $177.39 on Friday. The business’s 50 day moving average is $169.09 and its 200-day moving average is $158.25. VanEck Biotech ETF has a 1-year low of $135.34 and a 1-year high of $179.81.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.